[Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
OBJECTIVE
Measles, mumps, rubella and varicella zoster virus (VZV) infections are regarded as typical diseases of childhood: They are normally clinically mild and result in lifelong immunity. Severe clinical disease is known in immunocompromised patients; rubella virus infections during pregnancy often result in congenital rubella syndrome. All these diseases are preventable by vaccination which is recommended in Germany, recently vaccination against VZV for teenager without immunity since July 2001. In the following study we screened for immunity against the four viruses.


METHODS
Serum samples were obtained at the Institute of Medical Virology Frankfurt/Main from January 1999 until December 2000. We tested for specific antibodies against measles (n = 915), against mumps (n = 857), against rubella (n = 1886) and against VZV (n = 2291). Seroprevalences were determined in different age groups.


RESULTS
Altogether the highest rate of seronegatives is detected in younger children. VZV-seronegativity rates decrease from 74 % to 32 % in younger children. Against rubella also in this age group rate of seronegatives is found in 40 % and less than 10 % by teenagers. From this age group also immunity against rubella is found approximately in 80 % of seropositives.


CONCLUSIONS
The following study shows that high seronegative rates are detectable, and here specially against VZV-specific antibodies. For seronegative teenagers, vaccination against VZV is now recommended in Germany. Immunization rates of at least 95 % in childhood would be effective in avoiding severe courses of disease and giving protection in pregnancy.
Buxbaum
S
S
Institut für Medizinische Virologie der Universitätsklinik Frankfurt/Main, Germany. S.Buxbaum@em.uni-frankfurt.de
Doerr
H W
HW
Allwinn
R
R
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000914:Antibodies, Viral / Q000032:analysis; D002644:Chickenpox / Q000276:immunology* / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005858:Germany; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008457:Measles / Q000276:immunology* / Q000517:prevention & control; D008459:Measles virus / Q000276:immunology; D008875:Middle Aged; D009107:Mumps / Q000276:immunology* / Q000517:prevention & control; D009109:Mumps virus / Q000276:immunology; D011247:Pregnancy; D012409:Rubella / Q000276:immunology* / Q000517:prevention & control; D012412:Rubella virus / Q000276:immunology; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage
D000914:Antibodies, Viral; D014765:Viral Vaccines